FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Videos|May 25, 2015
NASP and Specialty Pharmacy Times Join to Enhance the Specialty Landscape
Author(s)Davy James, Managing Editor
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the partnership between the National Association for Specialty Pharmacy and Specialty Pharmacy Times.
Advertisement
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the partnership between the National Association for Specialty Pharmacy and Specialty Pharmacy Times.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Advertisement
Related to this article
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
5